News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …
Key Points CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we like better than CRISPR Therapeutics › CRISPR Therapeutics(NASDAQ: CRSP) has had …
CRISPR Therapeutics AG (CRSP) ended the recent trading session at $48.44, demonstrating a +1.68% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.66%. Elsewhere, the Dow saw an upswing of 1.19%, while the …
Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable, potentially resulting in massive gains. Three mid-cap …
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this company have returned -17.1% over …
Wall Street expects a year-over-year increase in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its …
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 2.08% at $46.54. This move lagged the S&P 500's daily gain of 0.05%. At the same time, the Dow added 0.46%, and the tech-heavy Nasdaq lost 0.64%. The company's shares have seen a …
If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. CRISPR Therapeutics stock has delivered a decline of about 61% over the past five years, yet current valuation checks suggest the shares now …
Search by ticker symbol or company name and select a result to open its chart.